Connection
Eric Wu to Bevacizumab
This is a "connection" page, showing publications Eric Wu has written about Bevacizumab.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.047 |
|
|
|
-
Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study. Lung Cancer. 2014 Dec; 86(3):350-7.
Score: 0.026
-
Yang H, Yu AP, Wu EQ, Yim YM, Yu E. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. J Med Econ. 2011; 14(5):542-52.
Score: 0.021